The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the "gastric barrier effect" in patients chronically treated with PPI: A pilot study

Journal of Clinical Gastroenterology

Volumn 46, Issue SUPPL. 1, 2012, Pages

  Del Piano, Mario ^a   Anderloni, Andrea ^a   Balzarini, Marco ^a   Ballarè, Marco ^a   Carmagnola, Stefania ^a   Montino, Franco ^a   Orsello, Marco ^a   Pagliarulo, Michela ^a   Tari, Roberto ^a   Soattini, Liliana ^b   Sforza, Filomena ^b   Mogna, Luca ^c   Mogna, Giovanni ^d  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b Private Hospital i Cedri   (Italy)

^c Biolab Research Srl   (Italy)

^d Probiotical SpA   (Italy)

Author keywords

gastric bacterial overgrowth; gastric barrier effect; probiotic strain; proton pump inhibitors (PPIs)

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; LDD 01; LP 01; LPS 01; LR 06; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL GROWTH; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DUODENUM; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; GASTROSCOPY; HUMAN; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PENTOSUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STOMACH; STOMACH JUICE;

BACTERIAL LOAD; DUODENUM; ENTEROBACTERIACEAE; ENTEROCOCCUS; FEMALE; GASTRIC JUICE; GASTROESOPHAGEAL REFLUX; HUMANS; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; MALE; PILOT PROJECTS; PROBIOTICS; PROTON PUMP INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YEASTS;

EID: 84866254547     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318267b55d     Document Type: Article

References (44)

1. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361:512-519. (Pubitemid 36173720)
2. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H2 receptor antagonists and proton pump inhibitors for the practicing physician. Best Pract Res Clin Gastroenterol. 2001;15:355-370. (Pubitemid 32590872)
3. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, superoxide production, degranulation and translocation on cytochrome b-245. Gut. 1992;33:617-621.
4. Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967;8:74-81.
5. Meuwissen SG, Craanen ME, Kuipers EJ. Gastric mucosal morphological consequences of acid suppression: a balance view. Best Pract Res Clin Gastroenterol. 2001;15: 497-510. (Pubitemid 32590882)
6. Hill M. Normal and pathological microbial of the upper gastrointestinal tract. Scand J Gastroenterol. 1984;20(suppl 111): 111-115.
7. Dellipiani AW, Girdwood RH. Bacterial changes in the small intestine in malabsorption states and in pernicious anaemia. Clin Sci. 1964;26:359-374.
8. Mowat C, Williams C, Gillen D, et al. Omeprazole, Helicobacter pylori status and alteration in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology. 2000;119:339-347. (Pubitemid 30621984)
9. Sandeanu S, Jonkers D, De bruine A, et al. Non-Helicobacter pylori bacterial flora during acid suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15:379-388. (Pubitemid 32187560)
10. Tenaillon O, Skurnik D, Picard B, et al. The population genetics of commensal Escherichia coli. Nat Rev Microbiol. 2010;8:207-217.
11. Serna A IV, Boedeker EC. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol. 2008;24:38-47. (Pubitemid 350190896)
12. Ferens WA, Hovde CJ. Escherichia coli O157:H7: animal reservoir and sources of human infection. Foodborne Pathog Dis. 2011;8:465-487.
13. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. First American Cancer society award lecture in cancer epidemiology and prevention. Cancer Res. 1992;52:6735-6740. (Pubitemid 23006271)
14. Blot WJ. Alcohol and cancer. Cancer Res.. 1992;52(suppl 7): 2119-2123.
15. Zavros Y, Roeder G, Ferguson A, et al. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology. 2002;122:119-133. (Pubitemid 34049201)
16. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018-1022. (Pubitemid 26123777)
17. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd study group. Gastroenterology. 1999;117:319-326. (Pubitemid 29352939)
18. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661-669. (Pubitemid 30171615)
19. Sanduleanu S, Jonkers D, De Bruine A, et al. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of proinflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 2001;15:1163-1175. (Pubitemid 32675450)
20. Hurst AF. The clinical importance of achlorhydria. Br Med J. 1934;2:665-669.
21. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693-1703.
22. Canani RB, Cirillo P, Roggero P, et al. Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817-e820. (Pubitemid 46071346)
23. Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994;35:23-26. (Pubitemid 24059466)
24. Walter J, Tannock GW, Tilsala-Timisjarvi A, et al. Detection and identification of gastrointestinal Lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl Environ Microbiol. 2000;66:297-303. (Pubitemid 30030531)
25. Byun R, Nadkarni MA, Chhour KL, et al. Quantitative analysis of diverse Lactobacillus species present in advanced dental caries. J Clin Microbiol. 2004;42:3128-3136. (Pubitemid 38938069)
26. Torriani S, Felis GE, Dellaglio F. Differentiation of Lactobacillus plantarum, L. pentosus, and L. paraplantarum by recA gene sequence analysis and multiplex PCR assay with recA genederived primers. Appl Environ Microbiol. 2001;67:3450-3454. (Pubitemid 33641213)
27. Lick S, Drescher K, Heller KJ. Survival of Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus in the terminal ileum of fistulated Gö ttingen minipigs. Appl Environ Microbiol. 2001;67:4137-4143. (Pubitemid 33641709)
28. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72:437-445.
29. Chen J, Yuan YC, Leontiadis GI, et al. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46: 93-114.
30. Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124:519-526.
31. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931-950.
32. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA. 2004;292:1955-1960. (Pubitemid 39411203)
33. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167:950-955. (Pubitemid 46762758)
34. Roughead EE, Ramsay EN, Pratt NL, et al. Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust. 2009;190:114-116.
35. Leonard J, Marshall JK, Moayyedi Pl. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047-2056. (Pubitemid 47301504)
36. Aslam S, Darouiche RO. Role of antibiofilm-antimicrobial agents in controlling device-related infections. Int J Artif Organs. 2011;34:752-758.
37. Brenner DJ, David BR, Steigerwalt AG. Atypical biogroups of Escherichia coli found in clinical specimens and description of Escherichia hermannii sp. nov. J Clin Microbiol. 1982;15:703-713. (Pubitemid 12135629)
38. AllenMJ, Edberg SC. The Public Health Significance of Bacterial Indicators in Drinking Water. The Royal Society of Chemistry 1999. UK: Special Publication. Athenaeum Press; 1995.
39. Gérôme P, Bourilhon N, Soullie B, et al. Acute appendicitis due to both Klebsiella pneumoniae and serotype 35B Streptococcus pneumoniae, an emergent serotype. Ann Biol Clin (Paris). 2011;69:485-488.
40. Joainig MM, Gorkiewicz G, Leitner E, et al. Cytotoxic effects of Klebsiella oxytoca strains isolated from patients with antibiotic-associated hemorrhagic colitis or other diseases caused by infections and from healthy subjects. J Clin Microbiol. 2010;48:817-824.
41. Qureshi ZA, Paterson DL, Pakstis DL, et al. Risk factors and outcome of extended-spectrum b-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents. 2011;37:26-32.
42. Murray BE, Weinstock GM. Enterococci: new aspects of an old organism. Proc Assoc Am Physicians. 1999;111:328-334. (Pubitemid 29331465)
43. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med. 2009;360: 439-443.
44. Top J, Willems R, Bonten M. Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen. FEMS Immunol Med Microbiol. 2008;52:297-308. (Pubitemid 351420752)